AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's drug Enhertu, in combination with pertuzumab, has received breakthrough therapy status in the U.S. for treating adults with advanced HER2 positive breast cancer that cannot be surgically removed.
Enhertu is an antibody drug that targets HER2, developed by Daiichi Sankyo and AstraZeneca together.
5 hours ago
1
English (US) ·